The biosimilar will be available to any licensed specialty pharmacy in the United States at a 95% discount from Stelara, starting January 1, 2026.

MedImpact Holdings is planning to offer an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than Stelara. The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals ...

Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos ® (Zongertinib). The Food and Drug Administration approved ...

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares edged slightly higher on Tuesday. The firm’s specialty pharmacy arm ...

Walgreens Specialty Pharmacy, which earned $25.9 billion last year from U.S. prescription revenue, has expanded its limited distribution drug portfolio to 265 medications, the company said Aug. 19. ...

Spotlight PA is an independent, nonpartisan, and nonprofit newsroom producing investigative and public-service journalism ...

Pharmacy leaders at health systems across the country say preserving the intent of the federal 340B drug pricing program and increasing transparency around pharmacy benefit managers are the most ...

We analyzed specialty drug coverage decisions issued by the largest US commercial health plans to examine variation in coverage and the consistency of those decisions with indications approved by t ...

TROY, Mich.: 29 July 2025 — As a steadily rising number of neighborhood drug stores close their doors, more customers are turning to mail order pharmacies, mass market merchandisers and ...